CEO Update|Tuesday 26 May

AstraZeneca receives $1.2bn to scale-up and deliver Oxford’s COVID-19 vaccine, antibody testing gains momentum as a deal is struck between Roche and the NHS and details start to emerge on the future of the UK’s relationship with the EU.

Guest Blog|A reflection on the Lighthouse Lab journey so far

Last month, UK government approached Medicines Discovery Catapult, based at Alderley Park, to coordinate the establishment of the national megalabs for the testing of COVID-19.

BIA welcomes new NIHR framework for restarting research activities in the UK

Commenting on the NIHR 'Framework for restart' released today, Steve Bates OBE, Chief Executive of the BIA said: 

Guest Blog|How do pandemics impact the life sciences industry?

Pharmaceutical, healthcare and biotech companies are at the forefront of the COVID-19 response, from therapeutic drug trials and vaccine development to the production of personal protective equipment (PPE) and ventilators.

BIA responds to government approach to Northern Ireland Protocol

Commenting on the Government’s approach to the Northern Ireland Protocol released yesterday, Steve Bates OBE, Chief Executive of the BioIndustry Association said:

Oxford Immunotec releases the T-SPOT® Discovery™ SARS-CoV-2 kit for research into measuring the T cell immune response to SARS-CoV-2, which may offer new insights into immunity to COVID-19

Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces the release of the T-SPOT Discovery SARS-CoV-2 test kit. This kit is for research use only and launched under the T-SPOT Discovery brand. This research kit could make a significant contribution towards development of a new tool to manage the COVID-19 pandemic, which in turn could help to bring nations out of their current lockdowns in a faster, safer and more controlled manner.

BIA welcomes financial support for biotechs during COVID-19 disruption

A new support fund for innovative firms struggling to access equity finance during the COVID-19 disruption has opened for applications today (20 May). The Future Fund, run by the British Business Bank, will provide convertible loans of between £125,000 and £5m to businesses if they can also secure matched funding from third-party investors.

BIA responds to publication of draft UK-EU free trade agreement

Commenting on the publication of draft UK-EU free trade agreement text released today Steve Bates OBE, Chief Executive of the BIA said:

Locate Bio announces the appointment of John von Benecke as CEO

Locate Bio Ltd (“Locate”), an orthobiologics company pursuing multiple high value spinal opportunities, announced that John von Benecke has been appointed CEO to drive Locate’s lead program for spinal fusion and continue to build out its spinal pipeline.

Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform to complement cell line development offering for difficult-to-express proteins

CHOSOURCE platform to be combined with Rentschler Biopharma’s novel in-house cell line development process to provide speed, stability and high yield